Image pharmaphorum Editor Podcasts The future biosimilar landscape: the pharmaphorum podcast For episode 3 of the pharmaphorum podcast Dominic Tyer went to the UK headquarters of Sandoz to meet the head of the compa Debates & Insight Sponsored Can simulated datasets unlock the potential of patient data? Overview Views & Analysis Strategic planning in increasingly complex and uncertain mar... This article is the first in a series of three from Osprey Health Consulting that address the contemporary challenges facing strategic brand planners dealing with increasingly complex and uncertain News Amgen invests £50m in UK genetics firm Oxford Nanopore Biotech giant Amgen has ploughed £50 million into a genetic sequencing company to support the development of its cutting-edge technology. Load more results
Podcasts The future biosimilar landscape: the pharmaphorum podcast For episode 3 of the pharmaphorum podcast Dominic Tyer went to the UK headquarters of Sandoz to meet the head of the compa
Views & Analysis Strategic planning in increasingly complex and uncertain mar... This article is the first in a series of three from Osprey Health Consulting that address the contemporary challenges facing strategic brand planners dealing with increasingly complex and uncertain
News Amgen invests £50m in UK genetics firm Oxford Nanopore Biotech giant Amgen has ploughed £50 million into a genetic sequencing company to support the development of its cutting-edge technology.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.